Stabilization and Improved in Vivo Performance of Amorphous Etoricoxib using Gelucire 50/13 View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2005-10

AUTHORS

Shamkant L. Shimpi, Bhaskar Chauhan, K. R. Mahadik, Anant Paradkar

ABSTRACT

PURPOSE: Amorphous drugs have gained importance because of their advantageous biopharmaceutical properties; however, their stabilization remains a challenge. The purpose of this work was to stabilize the amorphous form of etoricoxib (ET) by using a low excipient/drug ratio to improve drug dissolution and thus bioavailability. METHODS: The effect of Gelucire and polyvinylpyrrolidone (PVP) on stabilization and bioavailability of amorphous etoricoxib (AET) was studied. X-ray powder diffractometry, differential scanning calorimetry, and scanning electron microscopy were used to study the physical state of the drug. Dissolution studies were performed for melt granules of AET with Gelucire 50/13 (MG-AET) and solid dispersion with PVP (SDP) to differentiate dissolution performance. A stability study on samples was conducted for 3 months to evaluate the physical state of the drug and its dissolution in the formulation. The in vivo performance of the optimized and stable formulation of ET was evaluated in rat. RESULTS: Dissolution of MG-AET was significantly improved as compared to AET and SDP. Both factors, amorphization of drug and melt granulation with lipid, seemed to be important for improving dissolution. Stability data revealed that MG-AET was significantly advantageous for AET stabilization, whereas PVP was not. The amount of Gelucire required for the stabilization of one part of AET was 0.5 part (by weight), whereas even 1.5 part (by weight) of PVP failed to elicit the same result. The superior in vivo performance of MG-AET has been attributed to the altered physiochemical properties of AET and the presence of lipid in the system. CONCLUSION: Gelucire can stabilize AET and improve its biopharmaceutical performance at a low excipient/drug ratio and may provide a better alternative to conventional stabilizers such as PVP. More... »

PAGES

1727-1734

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11095-005-6694-1

DOI

http://dx.doi.org/10.1007/s11095-005-6694-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1033619280

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16180131


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0306", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Physical Chemistry (incl. Structural)", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/03", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Chemical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biological Availability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Calorimetry, Differential Scanning", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclooxygenase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Stability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Etoricoxib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fats", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Microscopy, Electron, Scanning", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Molecular Structure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oils", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfones", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Bharati Vidyapeeth Deemed University", 
          "id": "https://www.grid.ac/institutes/grid.411681.b", 
          "name": [
            "Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane Pune, 411 038, Maharashtra, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shimpi", 
        "givenName": "Shamkant L.", 
        "id": "sg:person.01077723237.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077723237.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bharati Vidyapeeth Deemed University", 
          "id": "https://www.grid.ac/institutes/grid.411681.b", 
          "name": [
            "Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane Pune, 411 038, Maharashtra, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chauhan", 
        "givenName": "Bhaskar", 
        "id": "sg:person.01150726052.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150726052.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bharati Vidyapeeth Deemed University", 
          "id": "https://www.grid.ac/institutes/grid.411681.b", 
          "name": [
            "Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane Pune, 411 038, Maharashtra, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mahadik", 
        "givenName": "K. R.", 
        "id": "sg:person.01232215633.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232215633.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Bharati Vidyapeeth Deemed University", 
          "id": "https://www.grid.ac/institutes/grid.411681.b", 
          "name": [
            "Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane Pune, 411 038, Maharashtra, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paradkar", 
        "givenName": "Anant", 
        "id": "sg:person.0740257351.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740257351.21"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.ijpharm.2003.11.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001150313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0378-5173(00)00485-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002350742"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0378-5173(95)04140-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002792916"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/bmc.359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005285375"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0378-5173(02)00019-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007625425"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejpb.2004.05.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008016452"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0223-5234(03)00015-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010589298"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0223-5234(03)00015-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010589298"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0928-0987(00)00173-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016269545"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/03639048809152004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021589606"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijpharm.2004.05.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021890583"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0378-5173(00)00325-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024992852"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0378-5173(01)00776-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027196060"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jps.10014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030397266"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1020905412654", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031073252", 
          "https://doi.org/10.1023/a:1020905412654"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijpharm.2004.06.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031456169"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0378-5173(02)00316-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046218313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jps.1054", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051186583"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jps.10085", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053582514"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-10", 
    "datePublishedReg": "2005-10-01", 
    "description": "PURPOSE: Amorphous drugs have gained importance because of their advantageous biopharmaceutical properties; however, their stabilization remains a challenge. The purpose of this work was to stabilize the amorphous form of etoricoxib (ET) by using a low excipient/drug ratio to improve drug dissolution and thus bioavailability.\nMETHODS: The effect of Gelucire and polyvinylpyrrolidone (PVP) on stabilization and bioavailability of amorphous etoricoxib (AET) was studied. X-ray powder diffractometry, differential scanning calorimetry, and scanning electron microscopy were used to study the physical state of the drug. Dissolution studies were performed for melt granules of AET with Gelucire 50/13 (MG-AET) and solid dispersion with PVP (SDP) to differentiate dissolution performance. A stability study on samples was conducted for 3 months to evaluate the physical state of the drug and its dissolution in the formulation. The in vivo performance of the optimized and stable formulation of ET was evaluated in rat.\nRESULTS: Dissolution of MG-AET was significantly improved as compared to AET and SDP. Both factors, amorphization of drug and melt granulation with lipid, seemed to be important for improving dissolution. Stability data revealed that MG-AET was significantly advantageous for AET stabilization, whereas PVP was not. The amount of Gelucire required for the stabilization of one part of AET was 0.5 part (by weight), whereas even 1.5 part (by weight) of PVP failed to elicit the same result. The superior in vivo performance of MG-AET has been attributed to the altered physiochemical properties of AET and the presence of lipid in the system.\nCONCLUSION: Gelucire can stabilize AET and improve its biopharmaceutical performance at a low excipient/drug ratio and may provide a better alternative to conventional stabilizers such as PVP.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11095-005-6694-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1094644", 
        "issn": [
          "0724-8741", 
          "1573-904X"
        ], 
        "name": "Pharmaceutical Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "22"
      }
    ], 
    "name": "Stabilization and Improved in Vivo Performance of Amorphous Etoricoxib using Gelucire 50/13", 
    "pagination": "1727-1734", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "a02695383bf1859d944e254faefad18fe2a62de12acca2d4df77402767fa42d9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16180131"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8406521"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11095-005-6694-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1033619280"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11095-005-6694-1", 
      "https://app.dimensions.ai/details/publication/pub.1033619280"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000361_0000000361/records_53999_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs11095-005-6694-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11095-005-6694-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11095-005-6694-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11095-005-6694-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11095-005-6694-1'


 

This table displays all metadata directly associated to this object as RDF triples.

197 TRIPLES      21 PREDICATES      60 URIs      34 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11095-005-6694-1 schema:about N1d43ecd7f5014741b8b07104f1498493
2 N47b8db07abdd41548ce6347a53d036b2
3 N4a444dbbdd2747b48e3a4e46a1b72a2d
4 N4fe7fab09808410d8923b0778bb8ea72
5 N5c4d845abf724d22b5a509bd1bcd01ef
6 N71e64fb74a624170913600c03eec5126
7 N8b4f48dabfd24b09bc108487868a806e
8 Na40323f9dc5446049fb6b55bd6600bcb
9 Nc8771e64acef4980a6fdfa2a3537b3b0
10 Ncc8dcc264d9540b189d23c9988f2208f
11 Nd4b3b04a5e464e858b7b08f2963b744a
12 Nf136fed9f4f34240b6216db3f2b3c9f1
13 Nf8390c0c6fd74d7ea65e8a9a3c63c7e5
14 anzsrc-for:03
15 anzsrc-for:0306
16 schema:author N2677d462465d43bea80f9a17905d6435
17 schema:citation sg:pub.10.1023/a:1020905412654
18 https://doi.org/10.1002/bmc.359
19 https://doi.org/10.1002/jps.10014
20 https://doi.org/10.1002/jps.10085
21 https://doi.org/10.1002/jps.1054
22 https://doi.org/10.1016/0378-5173(95)04140-0
23 https://doi.org/10.1016/j.ejpb.2004.05.011
24 https://doi.org/10.1016/j.ijpharm.2003.11.014
25 https://doi.org/10.1016/j.ijpharm.2004.05.005
26 https://doi.org/10.1016/j.ijpharm.2004.06.009
27 https://doi.org/10.1016/s0223-5234(03)00015-1
28 https://doi.org/10.1016/s0378-5173(00)00325-2
29 https://doi.org/10.1016/s0378-5173(00)00485-3
30 https://doi.org/10.1016/s0378-5173(01)00776-1
31 https://doi.org/10.1016/s0378-5173(02)00019-4
32 https://doi.org/10.1016/s0378-5173(02)00316-2
33 https://doi.org/10.1016/s0928-0987(00)00173-1
34 https://doi.org/10.3109/03639048809152004
35 schema:datePublished 2005-10
36 schema:datePublishedReg 2005-10-01
37 schema:description PURPOSE: Amorphous drugs have gained importance because of their advantageous biopharmaceutical properties; however, their stabilization remains a challenge. The purpose of this work was to stabilize the amorphous form of etoricoxib (ET) by using a low excipient/drug ratio to improve drug dissolution and thus bioavailability. METHODS: The effect of Gelucire and polyvinylpyrrolidone (PVP) on stabilization and bioavailability of amorphous etoricoxib (AET) was studied. X-ray powder diffractometry, differential scanning calorimetry, and scanning electron microscopy were used to study the physical state of the drug. Dissolution studies were performed for melt granules of AET with Gelucire 50/13 (MG-AET) and solid dispersion with PVP (SDP) to differentiate dissolution performance. A stability study on samples was conducted for 3 months to evaluate the physical state of the drug and its dissolution in the formulation. The in vivo performance of the optimized and stable formulation of ET was evaluated in rat. RESULTS: Dissolution of MG-AET was significantly improved as compared to AET and SDP. Both factors, amorphization of drug and melt granulation with lipid, seemed to be important for improving dissolution. Stability data revealed that MG-AET was significantly advantageous for AET stabilization, whereas PVP was not. The amount of Gelucire required for the stabilization of one part of AET was 0.5 part (by weight), whereas even 1.5 part (by weight) of PVP failed to elicit the same result. The superior in vivo performance of MG-AET has been attributed to the altered physiochemical properties of AET and the presence of lipid in the system. CONCLUSION: Gelucire can stabilize AET and improve its biopharmaceutical performance at a low excipient/drug ratio and may provide a better alternative to conventional stabilizers such as PVP.
38 schema:genre research_article
39 schema:inLanguage en
40 schema:isAccessibleForFree true
41 schema:isPartOf N425bcfa5d9fa4636aad3875f5d3755ce
42 N9e34ae13ad8749e09e952f28ae6fc885
43 sg:journal.1094644
44 schema:name Stabilization and Improved in Vivo Performance of Amorphous Etoricoxib using Gelucire 50/13
45 schema:pagination 1727-1734
46 schema:productId N2643794f58a7436aad8d2747977eced4
47 N5dd5232ad8b84d83a5ed52bc41b6ac4b
48 N7f4ec415e4b5463984f6ea662e13d91e
49 Nf8ebfcf74881401599a09e11951bdd3d
50 Nfc9be6bb0fe04a5ea7418c0227d411e7
51 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033619280
52 https://doi.org/10.1007/s11095-005-6694-1
53 schema:sdDatePublished 2019-04-11T12:13
54 schema:sdLicense https://scigraph.springernature.com/explorer/license/
55 schema:sdPublisher Nc4df46939db44a2ba740d641c6c12762
56 schema:url http://link.springer.com/10.1007%2Fs11095-005-6694-1
57 sgo:license sg:explorer/license/
58 sgo:sdDataset articles
59 rdf:type schema:ScholarlyArticle
60 N05490b8ff99843a9b7b665a047e57dab rdf:first sg:person.01232215633.78
61 rdf:rest Nde3ecb9ede814d2bb31210b43b64b6c7
62 N1d43ecd7f5014741b8b07104f1498493 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Pyridines
64 rdf:type schema:DefinedTerm
65 N2643794f58a7436aad8d2747977eced4 schema:name dimensions_id
66 schema:value pub.1033619280
67 rdf:type schema:PropertyValue
68 N2677d462465d43bea80f9a17905d6435 rdf:first sg:person.01077723237.95
69 rdf:rest N4e74d1956b7b426ab0d7ba319c0ae117
70 N425bcfa5d9fa4636aad3875f5d3755ce schema:issueNumber 10
71 rdf:type schema:PublicationIssue
72 N47b8db07abdd41548ce6347a53d036b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Animals
74 rdf:type schema:DefinedTerm
75 N4a444dbbdd2747b48e3a4e46a1b72a2d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Cyclooxygenase Inhibitors
77 rdf:type schema:DefinedTerm
78 N4e74d1956b7b426ab0d7ba319c0ae117 rdf:first sg:person.01150726052.80
79 rdf:rest N05490b8ff99843a9b7b665a047e57dab
80 N4fe7fab09808410d8923b0778bb8ea72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Rats
82 rdf:type schema:DefinedTerm
83 N5c4d845abf724d22b5a509bd1bcd01ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Fats
85 rdf:type schema:DefinedTerm
86 N5dd5232ad8b84d83a5ed52bc41b6ac4b schema:name pubmed_id
87 schema:value 16180131
88 rdf:type schema:PropertyValue
89 N71e64fb74a624170913600c03eec5126 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Molecular Structure
91 rdf:type schema:DefinedTerm
92 N7f4ec415e4b5463984f6ea662e13d91e schema:name doi
93 schema:value 10.1007/s11095-005-6694-1
94 rdf:type schema:PropertyValue
95 N8b4f48dabfd24b09bc108487868a806e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Biological Availability
97 rdf:type schema:DefinedTerm
98 N9e34ae13ad8749e09e952f28ae6fc885 schema:volumeNumber 22
99 rdf:type schema:PublicationVolume
100 Na40323f9dc5446049fb6b55bd6600bcb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Drug Stability
102 rdf:type schema:DefinedTerm
103 Nc4df46939db44a2ba740d641c6c12762 schema:name Springer Nature - SN SciGraph project
104 rdf:type schema:Organization
105 Nc8771e64acef4980a6fdfa2a3537b3b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Oils
107 rdf:type schema:DefinedTerm
108 Ncc8dcc264d9540b189d23c9988f2208f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Etoricoxib
110 rdf:type schema:DefinedTerm
111 Nd4b3b04a5e464e858b7b08f2963b744a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Microscopy, Electron, Scanning
113 rdf:type schema:DefinedTerm
114 Nde3ecb9ede814d2bb31210b43b64b6c7 rdf:first sg:person.0740257351.21
115 rdf:rest rdf:nil
116 Nf136fed9f4f34240b6216db3f2b3c9f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Calorimetry, Differential Scanning
118 rdf:type schema:DefinedTerm
119 Nf8390c0c6fd74d7ea65e8a9a3c63c7e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Sulfones
121 rdf:type schema:DefinedTerm
122 Nf8ebfcf74881401599a09e11951bdd3d schema:name nlm_unique_id
123 schema:value 8406521
124 rdf:type schema:PropertyValue
125 Nfc9be6bb0fe04a5ea7418c0227d411e7 schema:name readcube_id
126 schema:value a02695383bf1859d944e254faefad18fe2a62de12acca2d4df77402767fa42d9
127 rdf:type schema:PropertyValue
128 anzsrc-for:03 schema:inDefinedTermSet anzsrc-for:
129 schema:name Chemical Sciences
130 rdf:type schema:DefinedTerm
131 anzsrc-for:0306 schema:inDefinedTermSet anzsrc-for:
132 schema:name Physical Chemistry (incl. Structural)
133 rdf:type schema:DefinedTerm
134 sg:journal.1094644 schema:issn 0724-8741
135 1573-904X
136 schema:name Pharmaceutical Research
137 rdf:type schema:Periodical
138 sg:person.01077723237.95 schema:affiliation https://www.grid.ac/institutes/grid.411681.b
139 schema:familyName Shimpi
140 schema:givenName Shamkant L.
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077723237.95
142 rdf:type schema:Person
143 sg:person.01150726052.80 schema:affiliation https://www.grid.ac/institutes/grid.411681.b
144 schema:familyName Chauhan
145 schema:givenName Bhaskar
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150726052.80
147 rdf:type schema:Person
148 sg:person.01232215633.78 schema:affiliation https://www.grid.ac/institutes/grid.411681.b
149 schema:familyName Mahadik
150 schema:givenName K. R.
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01232215633.78
152 rdf:type schema:Person
153 sg:person.0740257351.21 schema:affiliation https://www.grid.ac/institutes/grid.411681.b
154 schema:familyName Paradkar
155 schema:givenName Anant
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740257351.21
157 rdf:type schema:Person
158 sg:pub.10.1023/a:1020905412654 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031073252
159 https://doi.org/10.1023/a:1020905412654
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1002/bmc.359 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005285375
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1002/jps.10014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030397266
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1002/jps.10085 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053582514
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1002/jps.1054 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051186583
168 rdf:type schema:CreativeWork
169 https://doi.org/10.1016/0378-5173(95)04140-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002792916
170 rdf:type schema:CreativeWork
171 https://doi.org/10.1016/j.ejpb.2004.05.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008016452
172 rdf:type schema:CreativeWork
173 https://doi.org/10.1016/j.ijpharm.2003.11.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001150313
174 rdf:type schema:CreativeWork
175 https://doi.org/10.1016/j.ijpharm.2004.05.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021890583
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1016/j.ijpharm.2004.06.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031456169
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1016/s0223-5234(03)00015-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010589298
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1016/s0378-5173(00)00325-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024992852
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/s0378-5173(00)00485-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002350742
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1016/s0378-5173(01)00776-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027196060
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1016/s0378-5173(02)00019-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007625425
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1016/s0378-5173(02)00316-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046218313
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1016/s0928-0987(00)00173-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016269545
192 rdf:type schema:CreativeWork
193 https://doi.org/10.3109/03639048809152004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021589606
194 rdf:type schema:CreativeWork
195 https://www.grid.ac/institutes/grid.411681.b schema:alternateName Bharati Vidyapeeth Deemed University
196 schema:name Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane Pune, 411 038, Maharashtra, India
197 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...